Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 170-177

  Parthasarathy, Hari K ^a   Alhashmi, Khamis ^c   McMahon, Alex D ^e   Struthers, Allan D ^b   McInnes, Gordon T ^e   Ford, Ian ^e   Connell, John M ^d   MacDonald, Thomas M ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aldosterone: renin ratio; Bendroflumethiazide; Plasma renin activity; Serum aldosterone; Spironolactone

Indexed keywords

ALDOSTERONE; BENDROFLUMETHIAZIDE; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 73849092227     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328332b79b     Document Type: Article

References (28)

1. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
2. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921-1926.
3. Kaplan NM. Deja vu for primary aldosteronism. Lancet 2008; 371:1890-1891.
4. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep 2007; 9:353-359.
5. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353:40.
6. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48:756-760.
7. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19:353-361.
8. Parthasarathy HK, Alhashmi K, McMahon AD, Struthers AD, Connell JM, McInnes GT, et al. Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. BMC Cardiovasc Disord 2007; 7:14.
9. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536.
10. Prasad N, MacFadyen RJ, Ogston SA, MacDonald TM. Elevated blood pressure during the first two hours of ambulatory blood pressure monitoring: a study comparing consecutive twenty-four-hour monitoring periods. J Hypertens 1995; 13:291-295.
11. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta 1980; 101:5-15.
12. MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, Rebuli R. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens 2008; 26:1695-1702.
13. Gandhi S, Santiesteban H. Resistant hypertension. Suggestions for dealing with the problem. Postgrad Med 1996; 100:97-102; 107-108
14. McAlister FA, Lewanczuk RZ, Teo KK. Resistant hypertension: an overview. Can J Cardiol 1996; 12:822-828.
15. MacDonald TM, Morant SV. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008; 65:775-786.
16. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318.
17. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14:311-315.
18. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854-2859.
19. Mosso L, Fardella C, Montero J, Rojas P, Sanchez O, Rojas V, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Chil 1999; 127:800-806.
20. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1):83s-85s.
21. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
22. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007; 116:268-275.
23. Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens 2005; 18:1631-1635.
24. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33-41.
25. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
26. Lim PO, Struthers AD, MacDonald TM. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 2002; 20:11-15.
27. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159-1164.
28. Freel EM, Ingram M, Wallace AM, White A, Fraser R, Davies E, Connell JM. Effectof variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects. Clin Endocrinol (Oxf) 2008; 68:700-706.